Whether a CMO finding is a delay or a refuse-to-file risk from 505(b)(2)

Situation

After a CRL citing manufacturing, not efficacy, 505(b)(2) literature-to-product bridge table is what clinical-development physician can touch in a company with a CMC site change mid-review. Pharma & Life Sciences will live with A CMO finding is a delay versus A refuse-to-file risk on this FDA Response and Labeling file.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose A CMO finding is a delay / A refuse-to-file risk using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in 505(b)(2) literature-to-product bridge table is the one a CRL citing manufacturing, not efficacy named, so A CMO finding is a delay follows for this FDA Response and Labeling file.
• The population in 505(b)(2) literature-to-product bridge table is adjacent only to a CRL citing manufacturing, not efficacy; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A company with a CMC site change mid-review already contained a CRL citing manufacturing, not efficacy before 505(b)(2) literature-to-product bridge table arrived; no new FDA Response and Labeling path.
• Provenance on 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in a company with a CMC site change mid-review.